TRV734 is a drug developed by Trevena Inc which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.[1]
Identifiers | |
---|---|
| |
PubChem CID |
|
Chemical and physical data | |
Formula | C22H28FN3O |
Molar mass | 369.484 g·mol−1 |
3D model (JSmol) |
|
| |
|